Loading
Latest filing published 19 Aug 2026 for Akari Therapeutics Plc, €11k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kameel D. Farag is a declared insider of Akari Therapeutics PLC, with filings sourced from SEC (Form 4). The record holds 12 filings, for trades running from 22 October 2025 to 17 August 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 19 August 2026, reports a share grant of €11k in Akari Therapeutics PLC. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations